DWP
KYNB

Daymark Wealth Partners’s Kyntra Bio KYNB Stock Holding History

Daymark Wealth Partners’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-596
Closed -$13.3K – 517
2024
Q2 		$13.3K Hold
596
– – ﹤0.01% 496
2024
Q1 		$35K Hold
596
– – ﹤0.01% 428
2023
Q4 		$13.2K Hold
596
– – ﹤0.01% 401
2023
Q3 		$12.9K Hold
596
– – ﹤0.01% 379
2023
Q2 		$40.2K Buy
+596
New +$246K ﹤0.01% 374

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Daymark Wealth Partners's KYNB Position: Q3 2024 in Review

Daymark Wealth Partners sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 596 shares — an estimated $13.3K sold.

Daymark Wealth Partners first reported a position in KYNB in Q2 2023 and held it in 5 quarters. The position peaked at $40.2K in Q2 2023. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Daymark Wealth Partners reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Daymark Wealth Partners sold 596 Kyntra Bio shares in Q3 2024, an estimated $13.3K.
  • Daymark Wealth Partners first reported a position in Kyntra Bio in Q2 2023 and held it in 5 quarters.
  • Daymark Wealth Partners's Kyntra Bio position peaked at $40.2K in Q2 2023.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Daymark Wealth Partners's 13F filing for Q3 2024, filed 8 Oct 2024.